(E)-ethyl 6-hydroxy-3-methylhex-2-enoate | 84978-36-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-ethyl 6-hydroxy-3-methylhex-2-enoate
• 英文别名: ethyl (E)-6-hydroxy-3-methyl-2-hexenoate；ethyl (E)-6-hydroxy-3-methylhex-2-enoate；ethyl 6-hydroxy-3-methyl-2-hexenoate
• CAS: 84978-36-9
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: AAVALQBMHPTCKX-BQYQJAHWSA-N

物化性质

• 沸点：
  271.7±23.0 °C(Predicted)
• 密度：
  1.004±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-ethyl 6-hydroxy-3-methylhex-2-enoate 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 ethyl 3-methyl-6-oxohex-2E-enoate
  参考文献：
  名称：

  Formal synthesis of degraded sterol (+)-aplykurodinone-1

  摘要：

  The formal synthesis of aplykurodinone-1 is accomplished starting from a suitably functionalized bicyclic lactone having the requisite cis-fused ring junction with a quaternary chiral center that was assembled following a Cp2TiCl-mediated radical cyclization protocol. Our synthetic route further elaborates implementation of Grubbs ring closing metathesis (RCM), Eschenmoser-Claisen rearrangement and iodo-lactonization reactions for the synthesis of the final tricyclic precursor of the target molecule. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.05.026
• 作为产物：
  描述：

  5-羟基-2-戊酮 在 4-二甲氨基吡啶 、 camphor-10-sulfonic acid 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 13.67h， 生成 (E)-ethyl 6-hydroxy-3-methylhex-2-enoate
  参考文献：
  名称：

  Formal synthesis of degraded sterol (+)-aplykurodinone-1

  摘要：

  The formal synthesis of aplykurodinone-1 is accomplished starting from a suitably functionalized bicyclic lactone having the requisite cis-fused ring junction with a quaternary chiral center that was assembled following a Cp2TiCl-mediated radical cyclization protocol. Our synthetic route further elaborates implementation of Grubbs ring closing metathesis (RCM), Eschenmoser-Claisen rearrangement and iodo-lactonization reactions for the synthesis of the final tricyclic precursor of the target molecule. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.05.026

文献信息

• Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative
  作者：Xingui Liu、Saikat Poddar、Lin Song、Howard Hendrickson、Xuan Zhang、Yaxia Yuan、Daohong Zhou、Guangrong Zheng

  DOI：10.1002/cmdc.201900676

  日期：2020.3.18

  A fluoro-substituted δ-tocotrienol derivative, DT3-F2, was synthesized. This compound was designed to stabilize the metabolically labile terminal methyl groups of δ-tocotrienol by replacing one C-H bond on each of the two methyl groups with a C-F bond. However, in vitro metabolic stability studies using mouse liver microsomes revealed an unexpected rapid enzymatic C-F bond hydrolysis of DT3-F2. To

  合成了氟取代的δ-生育三烯酚衍生物DT3-F2。该化合物被设计为通过用CF键取代两个甲基上每个的一个CH键来稳定δ-生育三烯酚的代谢不稳定的甲基。但是，使用小鼠肝微粒体进行的体外代谢稳定性研究表明，DT3-F2发生了意外的快速酶促CF键水解。据我们所知，这是烯丙基CF键异常代谢水解的第一个报道。
• Highly Selective and Catalytic Generation of Acyclic Quaternary Carbon Stereocenters via Functionalization of 1,3-Dienes with CO₂
  作者：Xiao-Wang Chen、Lei Zhu、Yong-Yuan Gui、Ke Jing、Yuan-Xu Jiang、Zhi-Yu Bo、Yu Lan、Jing Li、Da-Gang Yu

  DOI：10.1021/jacs.9b09721

  日期：2019.11.27

  limited to the construction of tertiary chiral centers. The asymmetric generation of acyclic products containing all-carbon quaternary stereocenters from substituted 1,3-dienes represents a more challenging, but highly desirable, synthetic process for which there are very few examples. Herein, we report the highly selective copper-catalyzed generation of chiral all-carbon acyclic quaternary stereocenters

  容易获得的 1,3-二烯的催化不对称官能化非常重要，但目前的例子主要限于三级手性中心的构建。由取代的 1,3-二烯不对称生成包含全碳四元立体中心的无环产物代表了一个更具挑战性但非常理想的合成过程，其例子很少。在此，我们报告了通过用 CO2 官能化 1,3-二烯，高选择性铜催化生成手性全碳无环四元立体中心。各种容易获得的 1,1-二取代的 1,3-二烯以及 1,3,5-三烯进行还原性羟甲基化，具有高化学选择性、区域选择性、E/Z 选择性和对映选择性。报告的方法具有良好的官能团耐受性，很容易放大到至少 5 mmol 起始二烯，并生成手性产品，这些产品是进一步衍生化的有用构建单元。进行了使用密度泛函理论计算的系统力学研究，并为涉及 的不对称转化提供了第一个理论研究。这些计算结果表明 1,3-二烯的 1,2-氢铜反应以高 π 面选择性进行以生成 (S)-烯丙基铜中间体，这进一步诱导了最终产
• Quinine derivatines
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04818441A1

  公开（公告）日：1989-04-04

  A compound of the general formul: ##STR1## wherein .alpha. .beta. means a saturated bond or a double bond; each R independently of one another is a methyl group or a methoxy group, or two R's taken together represent a group of --CH.dbd.CH--CH.dbd.CH--; n is zero or an integer of 1 through 9; when .alpha. .beta. is a saturated bond, R.sub.2 is a hydrogen atom or hydroxyl group, and when .alpha. .beta. is a double bond, R.sub.2 is a hydrogen atom; when .alpha. .beta. is a double bond or when R.sub.2 is a hydroxyl group, R.sub.1 is a carboxyl group, a group of CH.sub.2.sub.2m OH (wherein m is an integer of 1 through 3) or a group of ##STR2## (wherein m is an integer of 1 through 3); when .alpha. .beta. is a saturated bond and R.sup.2 is a hydrogen atom, R.sub.1 is a hydroxymethyl group or a group of ##STR3## (wherein m is an integer of 1 through 3) has pharmacological actions such as membrane stabilizing activity (e.g. lysosomal membrane stabilizing activity), mitochondrial electron transport activity, hypotensive activity, activity to inhibit cardiac hypertrophy, tracheal muscle relaxant activity, cerebral circulation improving activity and cerebral ischemia preventive activity and is of value in the prophylaxis and treatment of hypertension, cardiac failure, asthma, cerebral apoplexy and other diseases, as a cardiac failure remedy, bronchodilator, cerebral circulation improving agent or the like.

  通用式为：##STR1## 其中 .alpha. .beta. 表示饱和键或双键；每个R独立地是一个甲基基团或一个甲氧基基团，或者两个R一起代表一个--CH.dbd.CH--CH.dbd.CH--基团；n为零或1至9的整数；当 .alpha. .beta. 是饱和键时，R.sub.2 是一个氢原子或羟基，当 .alpha. .beta. 是双键时，R.sub.2 是一个氢原子；当 .alpha. .beta. 是双键或当 R.sub.2 是羟基时，R.sub.1 是一个羧基、一个CH.sub.2.sub.2m OH基团（其中m为1至3的整数）或一个##STR2## 基团（其中m为1至3的整数）；当 .alpha. .beta. 是饱和键且R.sup.2 是一个氢原子时，R.sub.1 是一个羟甲基基团或一个##STR3## 基团（其中m为1至3的整数）具有药理作用，如膜稳定作用（例如溶酶体膜稳定作用）、线粒体电子传递作用、降压作用、抑制心肌肥大作用、气管平滑肌松弛作用、改善脑循环活性和预防脑缺血活性，并且在高血压、心力衰竭、哮喘、脑卒中等疾病的预防和治疗中具有价值，可用作心力衰竭疗法、支气管扩张剂、改善脑循环剂等。
• PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
  申请人：Mitobridge, Inc.

  公开号：US10188627B2

  公开（公告）日：2019-01-29

  Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).

  本文提供的式 (I) 化合物可用于治疗 PPAR-delta 相关疾病（如线粒体疾病、肌肉疾病、血管疾病、脱髓鞘疾病和代谢性疾病）。
• [EN] PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] AGONISTES, COMPOSÉS, COMPOSITIONS PHARMACEUTIQUES PPAR ET MÉTHODES D'UTILISATION DE CEUX-CI
  申请人：MITOBRIDGE INC

  公开号：WO2016057660A8

  公开（公告）日：2016-05-19